Inozyme Pharma (NASDAQ:INZY) Rating Reiterated by HC Wainwright

HC Wainwright reiterated their buy rating on shares of Inozyme Pharma (NASDAQ:INZY) in a research report report published on Tuesday morning, Benzinga reports. HC Wainwright currently has a $14.00 price target on the stock.

Several other research firms have also weighed in on INZY. Wedbush reiterated an outperform rating and issued a $15.00 price objective on shares of Inozyme Pharma in a research note on Tuesday, May 7th. Wells Fargo & Company started coverage on shares of Inozyme Pharma in a research report on Thursday, May 30th. They set an overweight rating and a $14.00 target price on the stock. Bank of America lowered their price objective on Inozyme Pharma from $16.00 to $14.00 and set a buy rating for the company in a research report on Tuesday, April 9th. Finally, Needham & Company LLC reissued a buy rating and issued a $23.00 price target on shares of Inozyme Pharma in a research note on Wednesday, May 8th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Inozyme Pharma presently has an average rating of Buy and a consensus target price of $16.00.

Inozyme Pharma Stock Up 1.6 %

Shares of Inozyme Pharma stock opened at $4.49 on Tuesday. Inozyme Pharma has a 12-month low of $2.69 and a 12-month high of $7.80. The stock has a market capitalization of $277.75 million, a P/E ratio of -3.28 and a beta of 1.53. The company has a quick ratio of 14.05, a current ratio of 14.05 and a debt-to-equity ratio of 0.38. The stock has a 50 day moving average price of $4.60 and a two-hundred day moving average price of $5.08.

Inozyme Pharma (NASDAQ:INZY) last announced its earnings results on Tuesday, May 7th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.03). Equities analysts expect that Inozyme Pharma will post -1.59 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Values First Advisors Inc. bought a new stake in shares of Inozyme Pharma during the 4th quarter worth approximately $59,000. SG Americas Securities LLC raised its holdings in shares of Inozyme Pharma by 46.9% in the 4th quarter. SG Americas Securities LLC now owns 21,236 shares of the company’s stock valued at $90,000 after purchasing an additional 6,784 shares during the period. Superstring Capital Management LP acquired a new position in Inozyme Pharma during the fourth quarter worth approximately $528,000. Schonfeld Strategic Advisors LLC raised its stake in Inozyme Pharma by 346.8% in the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 311,880 shares of the company’s stock valued at $1,310,000 after acquiring an additional 242,080 shares during the period. Finally, Laurion Capital Management LP boosted its holdings in shares of Inozyme Pharma by 170.5% during the 3rd quarter. Laurion Capital Management LP now owns 677,329 shares of the company’s stock worth $2,845,000 after buying an additional 426,961 shares during the period. Institutional investors and hedge funds own 88.30% of the company’s stock.

About Inozyme Pharma

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.